Table 2.
Diagnostic follow-up characteristics of HCC patients (n=655)
| Variable | No delay (Diagnostic follow-up ≤60 days) (%) n=348 |
Diagnostic delay >60 days (%) n=307 |
P-value |
|---|---|---|---|
| Diagnostic evaluation method | - | - | <0.001 |
| Imaging | 261 (75.0) | 240 (78.2) | |
| Biopsy | 49 (14.1) | 59 (19.2) | |
| AFP only | 38 (10.9) | 8 (2.6) | |
| Diagnosis mechanism | - | - | <0.001 |
| Incidental | 20 (5.8) | 27 (8.8) | |
| Diagnostic | 229 (65.8) | 130 (42.3) | |
| Surveillance | 99 (28.5) | 150 (48.9) | |
| Provider adherence to AASLD guidelines | - | - | <0.001 |
| Yes | 292 (83.9) | 169 (55.1) | |
| No | 56 (16.1) | 138 (45.0) | |
| HCC cases non-adherent with AASLD guidelines reasoning¥ | - | - | 0.02 |
| Preliminary dx w/out evidence | 6 (10.9) | 12 (8.9) | |
| Evaluated by provider but inappropriate tests ordered or non-recognition | 29 (52.7) | 56 (41.5) | |
| Patient missed appointment or declined workup | 0 (0.0) | 5 (3.7) | |
| Contraindication to triple-phase contrast or biopsy | 14 (25.5) | 20 (14.8) | |
| Other | 6 (10.9) | 42 (31.11) | |
| Doubted diagnosis by provider | - | - | 0.06 |
| Primary care/inpatient | 11 (3.2) | 19 (6.2) | |
| GI specialist | 337 (96.8) | 288 (93.8) |
¥
n=190